In accordance with applicable privacy legislation, the company Kedrion S.p.a., controller of the data acquired via this website, hereby informs the user that said website does not use profiling cookies to send advertising messages tuned to preferences expressed when browsing the internet. This website installs third party cookies. Continuing to browse, including by scrolling down and clicking on website elements, equates to consent.
For more information, also as regards the technical cookies used by the website and to refuse consent to the installation of individual cookies, please refer to the complete cookies disclosure.
You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES
HIGHLIGHTS
PLASMA & BIOTHERAPIES
First patient enrolled and treated in Kedrion’s CARES10 clinical study
Phase 3 study to assess efficacy, safety and pharmacokinetics of a 10% IVIg in the treatment of adult PID patients
read moreEVENTS
June 27 and 28 in Trieste (Italy), a two-day event dedicated to hemophilia
Replacement therapy, personalization and access to treatment are the main themes of the congress organized by Kedrion
read moreEVENTS
16th International Hemophilia Congress in Turkey
A scientific symposium on the prevention and eradication of inhibitors in patients affected by Hemophilia A
read more
For more information please contact: pressoffice@kedrion.com
Where 